Johnson & Johnson plans to invest more than $1 billion in Jacksonville, Florida to strengthen its U.S. Vision operations by scaling manufacturing, packaging, and distribution capabilities. The investment includes the construction of a new, state-of-the-art distribution facility and advanced manufacturing technologies to expand capacity for its market-leading ACUVUE-brand contact lenses. This initiative aims to enhance supply chain resilience and meet the needs of more than 40 million patients in the U.S. and globally.

The investment is part of Johnson & Johnson's ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029. Construction of the new facility is underway with the goal of being fully operational in 2028. Building on more than 40 years of leadership in Florida, the project will support 3,500 Jacksonville employees and reinforces the company's $6 billion annual economic impact across the state.

Key Investment Details

Legacy and Operations

Johnson & Johnson's Jacksonville operations have advanced eye health for over four decades since establishing a presence in 1981. Today, the company manufactures more than 1.7 billion ACUVUE contact lenses annually for U.S. patients. The expansion is supported by more than 1.5 million square feet of manufacturing, research, distribution, and operations facilities in the region.

Johnson & Johnson announced results from the Phase 3 MonumenTAL-3 study demonstrating that TALVEY plus DARZALEX FASPRO significantly reduced the risk of disease progression or death by up to 72% in patients with relapsed or refractory multiple myeloma. The combination therapy showed a progression-free survival rate of 81.3% compared to 51.2% for the standard of care at 24 months. Overall survival rates reached 89.2% versus 79.1% for the control arm, marking the first Phase 3 study to show superior progression-free survival with a GPRC5D bispecific antibody combination in earlier-line multiple myeloma. These results reinforce Johnson & Johnson's leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding options to match the right treatment to the right patient and stage of disease.

The MonumenTAL-3 study evaluated TALVEY with DARZALEX FASPRO (Tal-D) or TALVEY with DARZALEX FASPRO and pomalidomide (Tal-DP) against the standard regimen of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd). At a median follow-up of 24.6 months, the hazard ratio for progression-free survival was 0.28 for Tal-DP and 0.33 for Tal-D. Statistically significant improvements were observed across key secondary endpoints, including overall response rate, complete response or better, and minimal residual disease-negative status.

Efficacy and Safety Results

The study enrolled 864 patients who had received at least one prior line of therapy, with 85.1% refractory to lenalidomide and 93.4% refractory to their last line of therapy. The overall safety profiles for the TALVEY plus DARZALEX FASPRO arms were consistent with the known profiles of each monotherapy. A reduced risk of severe infections was observed in the Tal-D arm compared to the standard of care, with Grade 3/4 infection rates of 29.2% for Tal-D, 37.7% for Tal-DP, and 42.2% for DPd.

Regulatory Submissions

Based on these results, Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for the use of TALVEY and DARZALEX FASPRO, with or without pomalidomide, for the treatment of relapsed or refractory multiple myeloma after at least one prior line of therapy. A Type II variation application has also been submitted to the European Medicines Agency. The results were presented at the 2026 European Hematology Association Annual Meeting and published in The New England Journal of Medicine.